A breakthrough or fast track approval of a new drug should be cause for celebration. However, bright times can quickly turn gloomy. If market demand is much greater than you expect, you’ll have trouble producing enough, which puts you at risk of stock-outs. Competitors can overtake you and you could lose market share or see your stock price fall but more importantly life changing drugs could fail reaching patients. If your product uptake is much slower than you had anticipated, then you will be paying for underutilized capacity with high production costs or cancellation fees.
What is needed to get this right, is the agility to change course from production commitment without slowing down or wasting money. If you have access to a flexible and tailored supply solution including a facility design that can rapidly scale up with your needs, demand volatility will not be an issue.
Ibex™ Dedicate is technology agnostic supply solution that helps you save up to 30 months-time to market and control investment risk with tailored business and ownership models.